文献速递前列腺癌

一种用于预测前列腺癌患者结局的四组尿液风险分类器

A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
PubMed 文献 · BJU Int · 2019-06-25

研究利用直肠指检后尿液来源细胞外囊泡RNA表达谱(n=535,多中心)构建基于LASSO的连续比率模型,生成四种前列腺尿液风险(PUR)特征以预测正常组织、D'Amico低危、中危和高危前列腺癌的概率。在测试队列(n=177)中进行诊断评估,在主动监测亚队列(n=87)中进行预后评估。各PUR特征与对应临床类别显著相关(P<0.001),PUR-4状态可预测具有临床意义的中危或高危疾病(AUC=0.77,95%CI 0.70-0.84),并在主动监测亚队列中与进展时间显著相关。

要点

  • PUR-4状态预测具有临床意义的中危或高危疾病,AUC=0.77(95%CI 0.70-0.84)。
  • 主动监测亚队列中,PUR状态和PUR-4比例与进展时间显著相关,四分位间距HR=2.86(95%CI 1.83-4.47,P<0.001)。
  • PUR-4连续使用时,尿液采集后5年进展率分别为10%和60%(HR=8.23,95%CI 3.26-20.81,P<0.001)。

核心结论

  • 尿液来源细胞外囊泡RNA可提供活检前侵袭性前列腺癌的诊断信息,以及主动监测男性的预后信息。
  • PUR代表一种新的多功能生物标志物,可能对当前前列腺癌患者的治疗产生实质性改变。

研究设计与样本

  • 研究纳入直肠指检后尿液来源细胞外囊泡RNA表达谱样本(n=535,多中心),使用定制的NanoString panel进行检测。
  • 构建基于LASSO的连续比率模型,生成四种前列腺尿液风险(PUR)特征,分别预测正常组织(PUR-1)、D'Amico低危(PUR-2)、中危(PUR-3)和高危(PUR-4)前列腺癌的概率。
  • 模型应用于测试队列(n=177)进行诊断评估,以及主动监测亚队列(n=87)进行预后评估。

主要发现

  • 每个PUR特征均与其对应的临床类别显著相关(P<0.001)。
  • PUR-4状态预测具有临床意义的中危或高危疾病,曲线下面积=0.77(95%CI 0.70-0.84)。
  • 应用PUR较当前临床实践提供净获益。
  • 在主动监测亚队列(n=87)中,由PUR状态和PUR-4比例定义的组别与进展时间显著相关(四分位间距风险比[HR]=2.86,95%CI 1.83-4.47;P<0.001)。
  • PUR-4连续使用时,将患者分为进展率不同的两组,尿液采集后5年进展率分别为10%和60%(HR=8.23,95%CI 3.26-20.81;P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a risk classifier using urine-derived extracellular vesicle (EV)-RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS). PATIENTS AND METHODS: Post-digital rectal examination urine-derived EV-RNA expression profiles (n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO-based continuation ratio model was built to generate four prostate urine risk (PUR) signatures for predicting the probability of normal tissue (PUR-1), D'Amico low-risk (PUR-2), intermediate-risk (PUR-3), and high-risk (PUR-4) prostate cancer. This model was applied to a test cohort (n = 177) for diagnostic evaluation, and to an AS sub-cohort (n = 87) for prognostic evaluation. RESULTS: Each PUR signature was significantly associated with its corresponding clinical category (P < 0.001). PUR-4 status predicted the presence of clinically significant intermediate- or high-risk disease (area under the curve = 0.77, 95% confidence interval [CI] 0.70-0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub-cohort (n = 87), groups defined by PUR status and proportion of PUR-4 had a significant association with time to progression (interquartile range hazard ratio [HR] 2.86, 95% CI 1.83-4.47; P < 0.001). PUR-4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection (HR 8.23, 95% CI 3.26-20.81; P < 0.001). CONCLUSION: Urine-derived EV-RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS. PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Connell SP, Yazbek-Hanna M, McCarthy F, et al. A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU Int. 2019. PMID: 31106513. doi:10.1111/bju.14811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。